Last quarter (Q4 2023), Nuvectis Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Nuvectis Pharma's net income was $-6.62M. See Nuvectis Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	$ 3.50M	$ 3.50M	$ -2.17M	-	-
Gross Profit	$ -3.50M	$ -3.50M	$ 2.17M	-	-
Operating Expense	$ 22.90M	$ 22.90M	$ 19.23M	$ 12.89M	$ 10.00K
Operating Income	$ -22.90M	$ -22.90M	$ -19.23M	$ -12.89M	$ -10.00K
Net Non Operating Interest Income Expense	-	-	-	$ 4.00K	$ 0.00
Other Income Expense	-	-	-	-	-
Pretax Income	$ -22.90M	$ -22.90M	$ -19.23M	$ -12.89M	$ -10.00K
Tax Provision	-	-	$ 0.00	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -22.26M	$ -22.26M	$ -19.09M	$ -12.89M	$ -10.00K
Basic EPS	$ -1.43	$ -1.43	$ -1.51	$ -1.09	$ >-0.01
Diluted EPS	$ -1.43	$ -1.43	$ -1.51	$ -1.09	$ >-0.01
Basic Average Shares	$ 62.23M	$ 15.56M	$ 12.66M	$ 12.72M	$ 12.72M
Diluted Average Shares	$ 62.23M	$ 15.56M	$ 12.66M	$ 12.72M	$ 12.72M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 26.39M	$ 26.39M	$ 17.06M	$ 12.89M	$ 10.00K
Net Income From Continuing And Discontinued Operation	$ -22.26M	$ -22.26M	$ -19.09M	$ -12.89M	$ -10.00K
Normalized Income	$ -10.29M	$ -18.09M	-	$ -12.89M	$ -10.00K
Interest Expense	-	-	-	-	-
EBIT	$ -22.90M	$ -22.90M	$ -19.23M	$ -12.89M	$ -10.00K
EBITDA	$ -16.74M	$ -22.90M	$ -19.23M	$ -12.89M	$ -10.00K

Currency in USD

Nuvectis Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing